

ERITREA Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea					
2. Grant number: 1821-ERI-18e-X / 18-ERI-18d-X / 18-ERI-08m-Y / 18-ERI-35b-Y					
3. Date of Decision Letter: 18 December 2017					
4. Date of the Partnership Framework Agreement: 16 April 2013					
5. Programme title: New Vaccine Support (NVS), Measles-Rubella first and second dose (two dose schedule) routine and Measles-Rubella catch-up campaign					
6. Vaccine type: Measles-Rubella					
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED					
8. Programme duration¹: 2018 - 2021					
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)					
	2018	2019	2020	2021	Total ²
Programme Budget (US\$) (Routine)	US\$32,500	US\$128,000	US\$115,500	US\$122,000	US\$398,000
Programme Budget (US\$) (Campaign)	US\$ 1,180,500				US\$ 1,180,500
Programme Budget (US\$) (TOTAL)	US\$ 1,213,000	US\$128,000	US\$115,500	US\$122,000	US\$ 1,578,500

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)³

Type of supplies to be purchased with Gavi funds in each year (Campaign)	2018
Number of Measles-Rubella vaccines doses	1,843,200
Annual Amounts (US\$)	US\$ 1,180,500
Type of supplies to be purchased with Gavi funds in each year (Routine)	2018
Number of Measles-Rubella vaccines doses	50,100
Annual Amounts (US\$)	US\$32,500

11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF

12. Self-procurement: Not applicable

13. Co-financing obligations for routine: Reference code: 1821-ERI-18e-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021
Number of vaccine doses	44,200	175,800	158,500	167,700
Value of vaccine doses (US\$)	US\$27,260			
Total co-financing payments (US\$) (including freight)	US\$28,500	US\$113,000	US\$101,500	US\$107,500
Minimum number of doses to be financed from domestic resources	21,224	83,935	75,204	79,060
Minimum amount to be financed from domestic resources (US\$)	US\$ 13,116	US\$ 51,872	US\$ 46,476	US\$ 48,859

14. Co-financing obligations for campaign: Not applicable

15. Vaccine introduction grant (in US\$): 100,000. Payable up to six months before vaccine introduction.

³ This is the amount that Gavi has approved.

16. Operational support for campaigns: Payable up to six months before campaign.

	2018
Grant amount (US\$)	US\$1,015,316

17. Additional reporting requirements:


Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles-Rubella campaign	Within 3 months of end of campaign
To submit the Post campaign coverage survey report for Measles-Rubella campaign	As soon as available

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

18 December 2017